CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus

Abstract

B cell generation of autoantibodies is a crucial step in the pathogenesis of systemic lupus erythematosus (SLE). After their differentiation in the bone marrow, B cells populate the secondary lymphatic organs, where they undergo further maturation leading to the development of memory B cells as well as antibody‐producing plasmablasts and plasma cells. Targeting B cells is an important strategy to treat autoimmune diseases like SLE, in which B cell tolerance is disturbed and autoimmune B cells and autoantibodies emerge. This review discusses the functional aspects of antibody‐ and cell‐based B cell depleting therapy in SLE. It thereby particularly focuses on lessons learned from chimeric antigen receptor (CAR) T cell treatment on the role of B cells in SLE for understanding B cell pathology in SLE. CAR T cells model a deep B cell depletion and thereby allow understanding the role of aberrant B cell activation in the pathogenesis of SLE. Furthermore, the effects of B cell depletion on autoantibody production can be better described, i.e. explaining the concept of different cellular sources of (auto‐) antibodies in the form of short‐lived plasmablasts and long‐lived plasma cells, which differ in their susceptibility to B cell depletion and require different targeted therapeutic approaches. Finally, the safety of deep B cell depletion in autoimmune disease is discussed.This article is protected by copyright. All rights reserved.

Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome

“…Assessment of changes of anti-GAD65 antibodies in CSF could have been more informative and should be considered in clinical trials. These findings demonstrate that CD19-expressing plasmablasts and short-lived plasma cells are susceptible to depletion by anti-CD19 CAR T cells ( 12 , 14 ). The reduction of anti-GAD65 titers may have contributed to the observed clinical improvement, even if a direct pathogenic role for these autoantibodies in SPS is still debated ( 15 ).…”

Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update

“…Although a better understanding of pathophysiology has improved the quality of patient care in the ICU setting and has led to increased in-hospital and overall survival [ 63 , 81 ], CAR-T cell management is currently based on few recommendations with high levels of evidence. All this could evolve over the coming years as the indications for this immunotherapy are extended to autoimmune diseases and solid cancers [ 82 , 83 ]. Whether related to the causative disease or to the complications of CAR-T cells, questions remain regarding the intensity of ICU management in case of CAR-T-related severe events.…”

“Rounding Third Base and Heading Home”: Arthritis & Rheumatology in 2024

“…Some of the concerns raised in the ACR comments included the cost to authors to publish manuscripts with immediate ("gold") OA, the potential for this requirement to hurt authors who are less well funded, and the downstream financial consequences of drastic reductions in subscription revenues to journals, such as A&R (and to their parent organizations, such as the ACR). Some journals will decide to publish a high volume of articles to make up for financial shortfalls; however, the Expert perspective: Immune checkpoint inhibitors and rheumatologic complications Simms, 2020 9 Expert perspectives on clinical challenges: expert perspectives: Challenges in scleroderma Arora and Rovin, 2022 10 Expert perspective: An approach to refractory lupus nephritis Nocturne and Mariette, 2023 11 Expert perspective: Challenges in Sjögren disease Patel and Stone, 2022 12 Expert perspective: Management of antineutrophil cytoplasmic antibody-associated vasculitis Case et al, 2022 13 Recognizing racial bias and promoting diversity in the rheumatology workforce Grayson et al, 2022 14 VEXAS syndrome and disease taxonomy in rheumatology Rome and Kesselheim, 2023 15 Biosimilar competition for Humira is here: Signs of hope despite early hiccups Dellaripa et al, 2023 16 The climate emergency and the health of our patients: The role of the rheumatologist Syversen et al, 2023 17 Therapeutic drug monitoring: A tool to optimize treatment of inflammatory joint diseases Calabrese et al, 2023 18 "Burnout" coupled with workforce shortages spells trouble: Innovative solutions are essential for more satisfying rheumatology practice Monach, 2024 19 Complement Taubmann et al, 2023 20 CAR-T cell treatment in systemic lupus erythematosus Crow et al, 2024 21 Standing on shoulders: Interferon research, from viral interference to lupus pathogenesis and treatment Hile and Werth, 2024 22 Understanding the role of type I IFN in cutaneous lupus and dermatomyositis: toward better therapeutics * CAR-T, chimeric antigen receptor T cell; IFN, interferon; VEXAS, vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome.…”